万维提示：
1、投稿方式：在线投稿。
2、期刊网址：https://ashpublications.org/blood
3、投稿网址：
https://blood.msubmit.net/cgi-bin/main.plex
4、官网邮箱：berliner.blood@hematology.org
roberts.blood@hematology.org
5、期刊刊期：周刊，每周出版一期。
2021年5月22日星期六
投稿须知【官网信息】
Guides & Checklists for Authors
Journal Scope
Blood, the flagship journal of the American Society of Hematology, published online and in print, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Acceptance of manuscripts is based on the originality and importance of the observations or investigations, the quality of the work and validity of the evidence, the clarity of presentation, and the relevance to our readership and field. All articles are expected to be concise, well organized and clearly written. Authors submit a manuscript with the understanding that the manuscript (or its essential substance) has not been published other than as an abstract in any language or format and is not currently submitted elsewhere for print or electronic publication.
Primary research articles will be published under the following scientific categories: Clinical Trials and Observations; Gene Therapy; Hematopoiesis and Stem Cells; Immunobiology and Immunotherapy scope; Myeloid Neoplasia; Lymphoid Neoplasia; Phagocytes, Granulocytes and Myelopoiesis; Platelets and Thrombopoiesis; Red Cells, Iron and Erythropoiesis; Thrombosis and Hemostasis; Transfusion Medicine; Transplantation; and Vascular Biology. Papers can be listed under more than one category as appropriate. Authors are invited to contact the Editor-in-Chief prior to submission if they are uncertain whether their work falls within the general scope of the journal.
Blood has recently formulated a more precise scope for immunobiology and immunotherapy, vascular biology, HIV/HTLV, and Clinical Trial submissions. The journal is very interested in submissions as reflected in the definitions linked below.
Immunobiology and Immunotherapy scope
Vascular Biology scope
HIV/HTLV scope
Clinical Trials scope
Blood welcomes submission of manuscripts reporting on clinical trials whether phase 1, 2, 3 or 4. Reports should include a full description of the study design, patient population, methodology and conduct, and statistical plan.
Immunobiology and Immunotherapy encompass a wide spectrum of research, but Blood can accommodate only papers that have clear and important implications for hematology. Preference is given to papers focusing on human immunobiology, immunotherapy, and immune pharmacology approaches in the human setting and those with significant implications for understanding of normal or malignant hematologic processes. Papers on tumor immunology, tumor vaccines and cancer immunotherapy development may be appropriate if the target cells or antigens are relevant to hematologic malignancies, but generally Blood cannot accommodate tumor immunology papers focusing solely on non-hematologic tumor types.
Papers investigating autoimmunity and utilizing non-hematologic models are not within the scope of Blood.
Vascular biology papers that focus primarily on atherosclerosis are outside the scope of Blood and instead should be considered for alternative journals.
Papers felt to be outside the scope of Blood will be returned to the author without full peer review.
Article Types
Original research articles
Regular Articles
Maximum length for a Regular Article is 4,000 words of text - counting only the Introduction, Methods, Results, and Discussion. Submissions are limited to a total of 7 figures, and digital images are required. We recommend a limit of 100 references. The sections of a Regular Article should be ordered as follows:
Abstract
Introduction
Methods
(must include sufficient information to allow readers to understand the article content)
Results
Discussion
Acknowledgements
Authorship Contributions
Disclosure of Conflicts of Interest
References
Tables
Figure Legends
Figures
Supplemental data - to be published online only - may include additional information regarding methodology, supplemental figures or tables, or primary data sets; it must be submitted with the original manuscript submission so it can be peer reviewed. (See "Supplemental data")
Any involvement of medical writers/researchers, particularly those employed or supported by the pharmaceutical industry, in the writing of an article must be clearly defined and disclosed in the Authorship and/or the Acknowledgements section(s) as appropriate. This type of involvement must also be disclosed to the Editor-in-Chief in the Cover Letter. For more information, see the journal Conflict of interest disclosure and the editorial policies for authors.
Definitive original research articles of exceptional scientific importance may be considered for designation as Plenary Papers. The decision to highlight an article as a Plenary Paper rests entirely with the Editors.
Systematic Review and Meta-analysis
The journal welcomes submission of systematic reviews with meta-analysis, which should be submitted as a Regular Article. A literature review should be performed and summarized. Data (where available) should be systematically extracted, and summative statistics should be presented where possible.
Brief Reports
Short manuscripts definitively documenting either experimental results or informative clinical observations will be considered for publication in this category. Single-case reports or case series cannot be accommodated unless they elucidate very novel and important disease biology or approaches to therapy. Brief Reports are not intended to allow publication of incomplete or preliminary findings. The review process is equally rigorous as for Regular Articles and the acceptance rate is lower. Brief Reports may not exceed 1,200 words of text -counting only the Introduction, Methods, Results, and Discussion. Abstracts must not exceed 200 words and should be a single paragraph with no subheadings. Only 2 figures/tables and 25 references may be included. The sections of a Brief Report should be ordered as follows:
Abstract
Introduction
Methods
(must include sufficient information to allow readers to allow reproduction of the data)
A combined Results and Discussion section
Acknowledgements
Authorship Contributions
Disclosure of Conflicts of Interest
References
Tables
Figure Legends
Figures
e-Blood
Some years ago, we created the e-Blood article type for manuscripts that presented novel datasets or methodologies with high relevance for hematology research. Over time, it has become increasingly common for a wide range of research papers to include significant supplemental datasets, and as a result we are now folding e-Blood into our Regular Article designation. Blood remains interested in these articles, and under the new article type designation they will be published both online and in print.
Other article types
Review Articles
Review articles are welcomed by the Journal and are generally solicited by the Editor-in-Chief; authors wishing to submit an unsolicited Review Article are invited to contact the Editor-in-Chief prior to submission in order to screen the proposed topic for relevance and priority, given other review articles that may already be in preparation. Review articles should focus on recent scientific or clinical advances in an area of broad interest to those in the field of hematology. Such articles must be concise and critical and should include appropriate references to the literature. All Review Articles, including those solicited by the Editors, are rigorously peer reviewed before a final publication decision is made.
Review articles should not exceed 4,000 words in length; the abstract must not exceed 250 words; we recommend a limit of 100 references. We wish for Review Articles to be written by experts who are personally committed to writing the manuscript, and therefore limit authorship to a maximum of 3 authors. The use of tables and color figures to summarize critical points is encouraged; the Journal offers assistance with preparation or improvement of figures by professional illustrators, once the article is accepted.
Pharmaceutical or medical device company employees and medical writers supported by a pharmaceutical or medical device company are not permitted to have any role in writing Review, Perspective, How I Treat, Blood Spotlight, or Evidence-based Focused Review articles. The use of editing services for non-English speakers is permissible, but it must be disclosed. Please direct any questions regarding this policy to the Editor-in-Chief prior to submission.
Special Reports
Special Reports encompass manuscripts that are neither reviews nor original reports of primary research. They may include consensus statements, guidelines, statements from task forces, or recommendations. Pharmaceutical or medical device company employees cannot act as authors, and medical writers supported by a pharmaceutical or medical device company are not permitted to have any role in writing Special Reports.
These articles should not exceed 4,000 words of body text and 250 words for the abstract; a limit of 100 references is recommended, although this can be flexible. Supplemental files are permitted. The use of tables and figures to summarize critical points is encouraged; the journal offers aid with preparation or improvement of figures by professional illustrators, once the article is accepted. The journal may also consider interactive links associated with the online article.
Perspectives
Perspectives are articles discussing significant topics and controversies relevant to hematology, generally from a more personal or opinion-based standpoint than a Review Article. Interested authors should correspond with the Editor-in-Chief prior to submission to discuss the suitability of the proposed subject matter. The length of the article should not exceed 4,000 words; the abstract must not exceed 250 words; we recommend a limit of 100 references. We wish for Perspectives to be written by experts who are personally committed to writing the manuscript, and therefore limit authorship to a maximum of 3 authors. Typically, Perspectives should state the topic and background information concisely, discuss opposing viewpoints, and make recommendations for further investigations or actions.
Pharmaceutical or medical device company employees and medical writers supported by a pharmaceutical or medical device company are not permitted to have any role in writing Review, Perspective, How I Treat, Blood Spotlight, or Evidence-based Focused Review articles. The use of editing services for non-English speakers is permissible, but it must be disclosed. Please direct any questions regarding this policy to the Editor-in-Chief prior to submission.
Blood Spotlight
Blood Spotlights are articles that focus on emerging scientific and clinical developments or a recent burst of advances on a particular theme in a circumscript area and are generally solicited by the Editor-in-Chief; authors wishing to submit an unsolicited Blood Spotlight are invited to contact the Editor-in-Chief prior to submission to allow screening of the proposed topic for relevance and priority in relation to other Spotlight articles that may already be in preparation. Spotlights deal with scientific or clinical topics that typically have surfaced in the last 1-3 years and that fomented a significant interest in the field of hematology. Spotlights must offer critical discussions in a highly condensed and succinct format. They should include appropriate references to the literature. All Blood Spotlights, including those solicited by the Editors, are rigorously peer reviewed before a final publication decision is made.
Blood Spotlights should not exceed 1,500-2,000 words in length, should include an abstract of no more than 80 words, and we recommend a limit of 80 references. We wish for Blood Spotlight articles to be written by experts who are personally committed to writing the manuscript, and therefore limit authorship to a maximum of 3 authors. Article titles should be concise. The inclusion of no more than 2 tables and/or figures to highlight and summarize critical points is encouraged; the Journal offers assistance with preparation or improvement of figures by professional illustrators, once the article is accepted.
Pharmaceutical or medical device company employees and medical writers supported by a pharmaceutical or medical device company are not permitted to have any role in writing Review, Perspective, How I Treat, Blood Spotlight, or Evidence-based Focused Review articles. The use of editing services for non-English speakers is permissible, but it must be disclosed. Please direct any questions regarding this policy to the Editor-in-Chief prior to submission.
How I Treat
The Journal welcomes articles written by expert clinicians offering up-to-date information and guidance regarding diagnosis and treatment of hematological diseases and clinical situations based on longstanding clinical experience. Each How I Treat article focuses on a single disease for which new information has recently emerged. Because many hematologic diseases are rare, their clinical management cannot always be based on large clinical trials. This increases the value of having articles authored by leading experts with in depth experience in the chosen disease.
How I Treat articles need to allow the clinical reader to gain greater insight into the biology of the disease and how it shapes clinical decision making through the synthesis of an expert clinician. Furthermore, these articles provide directions in the therapeutic management of common or complex clinical situations of the disease. The How I Treat articles contain illustrative clinical cases which should enhance their practical usefulness among the readers. The exemplary clinical cases in the text focus on the daily reality of clinical practice and present the information in an easily digestible format. Thus, the clinical cases need to be functionally integrated into the text for a full understanding of the issues and offer a link to the scientific background and diagnostic and therapeutic considerations in a practically meaningful way.
For instance, a How I Treat article could comprise: I. Introduction; II. Two to six cases each highlighting distinct clinically relevant issues and/or management dilemmas which are linked to the discussion that is presented; and III. Conclusion. Alternatively, one or two cases are presented that set the stage and are referred throughout the discussion. Selected supporting figures and tables are recommended. For examples see eg AM Vannucchi, How I treat polycythemia vera, Blood (2014) 124 (22): 3212-3220; G. Ossenkoppele and B. Löwenberg, How I treat the older patient with acute myeloid leukemia, Blood (2015) 125 (5): 767-774.
These pieces are generally solicited by the Editor-in-Chief, though any interested author should correspond with the Editor-in-Chief prior to submission to discuss the suitability of the proposed subject matter. We wish for How I Treat articles to be written by experts who are personally committed to writing the manuscript, and therefore limit authorship to a maximum of 2 authors. The length should not exceed 4,000 words; the abstract must not exceed 200 words; we recommend a limit of 100 references.
Pharmaceutical or medical device company employees and medical writers supported by a pharmaceutical or medical device company are not permitted to have any role in writing Review, Perspective, How I Treat, Blood Spotlight, or Evidence-based Focused Review articles. The use of editing services for non-English speakers is permissible, but it must be disclosed. Please direct any questions regarding this policy to the Editor-in-Chief prior to submission.
Blood Work
Blood welcomes submissions of photomicrographs and brief case descriptions to emphasize the value that the microscope adds to the history and physical exam. Blood Work places importance on the peripheral smear. The figure must clearly demonstrate the feature(s) being described and the discussion should emphasize this teaching point(s). The objective used (e.g. ×100 objective) should be stated within the text. Blood Work is an educational instrument to physicians and hematology students. Studies or case studies will not be accepted.
Each submission must contain a single, high-resolution figure (may be a composite) formatted as a TIFF (minimum 300 dpi) and a discussion of no more than 200 words describing the clinical case linked to the image and summary teaching point. Each piece should have a maximum of two authors and should not contain references. All other policies governing submissions to the Journal apply to Blood Work. There is no submission fee for Blood Work. For questions about submission to this section, please contact the Journal’s Editorial Office at editorial@hematology.org.
Accepted material will be submitted to the ASH Image Bank for the Editor-in Chief’s consideration.
Letters to Blood
The journal accepts original communications that bring out a focused but novel and important message on basic or clinical topics in hematology. All clinical submissions must have been approved by an ethics committee or institutional review board. Consideration for publication will be based on priority and interest to readership as determined by Editorial evaluation and peer review. In general, Letters to Blood report primary investigations that provide novel and important insights into hematologic biology or pathobiology, or the therapy of hematologic disease. Submissions are not intended to allow publication of incomplete or preliminary findings.
Single-case reports or small case series are considered in the Journal only if they offer truly important data elucidating disease biology or therapy.
Letters to Blood include no more than 1,200 words of text, 25 references, and 2 figures or tables. Letters have no abstract. A clear title is required. Letters to Blood are posted to First Edition, indexed by Medline, and appear in PubMed. Submission fees and page charges do not apply to Letters.
Blood Commentary
The Editors invite experts in the field to write brief commentaries introducing and placing into context selected primary research articles included in each issue of Blood.
e-Letters
Short, relevant comments that would expand reader understanding of Blood articles can be submitted as e-Letters. These contributions undergo a rapid editorial review and are posted shortly after acceptance. Further requirements and policies:
e-Letters must have no more than 10 authors
no more than 300 words of text
No more than 5 references
Tables and figures cannot be submitted
Any conflicts of interest (see Conflict of interest disclosure)
must accompany e-Letters
e-Letters that are not directly related to a published article, that duplicate points similar to those of already posted comments, or that are characterized by profanity, personal attacks, unprofessional tone or content, or offensive, abusive or libelous language will not be posted. Authors should pay special attention to spelling and grammar.
Authors of published articles are encouraged to respond with their own comments to e-Letters that have been posted in reference to their articles. e-Letters are not indexed by Medline.
……
更多详情：
https://ashpublications.org/blood/pages/authors-guides-checklists
